Madrigal Pharmaceuticals, Inc.
MDGL
$579.89
$6.741.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -289.13M | -281.90M | -391.59M | -465.89M | -518.67M |
| Total Depreciation and Amortization | 3.14M | 1.53M | 1.36M | 1.10M | 875.00K |
| Total Amortization of Deferred Charges | 1.62M | 1.77M | 1.87M | 2.09M | 2.36M |
| Total Other Non-Cash Items | 93.47M | 82.21M | 80.51M | 79.48M | 76.60M |
| Change in Net Operating Assets | 30.32M | -111.02M | -87.46M | -72.35M | 7.82M |
| Cash from Operations | -160.58M | -307.41M | -395.31M | -455.57M | -431.02M |
| Capital Expenditure | -1.05M | -974.00K | -1.11M | -1.46M | -2.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -42.16M | -37.63M | -207.46M | -272.92M | -586.26M |
| Cash from Investing | -43.21M | -38.61M | -208.56M | -274.39M | -588.56M |
| Total Debt Issued | 350.00M | -- | -- | -- | 0.00 |
| Total Debt Repaid | -121.66M | -- | -- | -- | -- |
| Issuance of Common Stock | 47.89M | 37.61M | 170.00M | 735.06M | 1.20B |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.42M | -- | -- | -- | 0.00 |
| Cash from Financing | 266.80M | 37.61M | 170.00M | 735.06M | 1.20B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.01M | -308.40M | -433.87M | 5.10M | 175.63M |